DelveInsight’s, “Bipolar Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Bipolar Depression Understanding
Bipolar Depression: Overview
Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).
Symptoms
During the manic phase, symptoms can include:
• High level of energy and activity
• Irritable mood
• Decreased need for sleep
• Exaggerated, puffed-up self-esteem ("grandiosity")
• Rapid or "pressured" speech
• Rapid thoughts
• Tendency to be easily distracted
• Increased recklessness
• False beliefs (delusions) or false perceptions (hallucinations)
Diagnosis
Since there are no medical tests to establish this diagnosis, a mental health professional diagnoses bipolar disorder based on a person's history and symptoms. The diagnosis is based not just on the current symptoms, but also take into account the problems and symptoms that have occurred through a person's life.
Treatment
A combination of medication and talk therapy is most helpful. Often more than one medication is needed to keep the symptoms in check.
Mood Stabilizers: The best-known and oldest mood stabilizer is lithium carbonate, which can reduce the symptoms of mania and prevent them from returning.
Antipsychotic Medications: In recent years, studies have shown that some of the newer antipsychotic medications can be effective for controlling bipolar disorder symptoms. Side effects often have to be balanced against the helpful effects of these drugs:
• Olanzapine: sleepiness, dry mouth, dizziness and weight gain.
• Risperidone: sleepiness, restlessness and nausea.
• Quetiapine: dry mouth, sleepiness, weight gain and dizziness.
• Ziprasidone: sleepiness, dizziness, restlessness, nausea and tremor.
• Aripiprazole: nausea, stomach upset, sleepiness (or sleeplessness) or restlessness.
• Asenapine: sleepiness, restlessness, tremor, stiffness, dizziness, mouth or tongue numbness.
Bipolar Depression Emerging Drugs Chapters
This segment of the Bipolar Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bipolar Depression Emerging Drugs
• Lumateperone: Intra-Cellular Therapies
Lumateperone is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia, and currently in development for bipolar depression and other neurological indications. The most common side effects include sleepiness and dry mouth.
• Zuranolone: SAGE Therapeutics
Zuranolone is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor.
Further product details are provided in the report……..
Bipolar Depression: Therapeutic Assessment
This segment of the report provides insights about the different Bipolar Depression drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Bipolar Depression
There are approx. 20+ key companies which are developing the therapies for Bipolar Depression. The companies which have their Bipolar Depression drug candidates in the most advanced stage, i.e. phase III include, SAGE Therapeutics.
• Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Depression drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve Bipolar Depression.
• In July 2019, Intra-Cellular Therapies announced top-line results from two Phase 3 clinical trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p<0.001; effect size = 0.56). Study 404 also met its key secondary endpoint, Clinical Global Impression Scale for Bipolar for Severity of Illness (CGI-BP-S) Total Score (p<0.001; effect size = 0.46). In both trials, lumateperone demonstrated a favorable safety profile and was generally well-tolerated.
Bipolar Depression Report Insights
• Bipolar Depression Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Bipolar Depression Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Bipolar Depression drugs?
• How many Bipolar Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bipolar Depression?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bipolar Depression and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Sunovion
• Sumitomo Pharmaceutical
• H. Lundbeck A/S
• NeuroRx, Inc.
• Korea Otsuka Pharmaceutical Co., Ltd.
• Intra-Cellular Therapies, Inc.
• Janssen Research & Development
• Forest Laboratories
• Celon Pharma
• Astellas Pharma Inc
• Iltoo Pharma

Key Products
• Lurasidone
• Vortioxetine
• Lumateperone
• JNJ-18038683
• Cariprazine
• Esketamine
• FK949E
• ILT101